Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • Acne
  • Atopic Dermatitis
  • Psoriasis
  • Rosacea
  • Skin Cancer
  • Anti-Aging
  • NPPA Community
  • Derm Pulse
MJH Life Sciences

SUBSCRIBE: Print / Digital / eNewsletter

The changing landscape of acne therapeutics: Page 4 of 4

acne

“A better understanding of acne pathophysiology and the role of inflammation has … yielded a better understanding of how existing therapies treat the disease and have led to more comprehensive treatment strategies that are multitargeted," says Leon Kircik, M.D., Icahn School of Medicine at Mount Sinai, New York.

  • Ingrid Torjesen
November 5, 2019
  • Acne, Drug Development
Leon Kircik, M.D.
Dr. Kircik

Systemic antiandrogens and hormonal modulation are already used to treat acne successful in some women, but there are concerns about systemic exposure.11 As clascoterone is applied topically and acts locally on androgen receptors in the skin, no systemic exposure has been seen and preliminary data from phase 2 trials suggest it has the potential to be an effective and a well-tolerated treatment.12

Researchers have found that cannabidiol (CBD), one of the 113 cannabinoids identified from Cannabis sativa, has anti-inflammatory properties which can prevent the proliferation of sebocytes,13 inhibit human keratinocyte proliferation14 and to possess potent antimicrobial activity against Gram-positive bacteria such as C. acnes.15

MORE ON ACNE: Read more stories here.

A synthetic cannabidiol topical formulation, BTX 1503, is being tested in acne, Dr Kircik says.

“Early clinical data confirm both the anti-inflammatory effects of topical BTX 1503 as well as its effects on noninflammatory lesions, with 4-week reductions in inflammatory lesion counts similar to what are reported in clinical trials for leading FDA-approved topical therapies in the same time frame,” he says.

 

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
References: 

1. Kircik LH. What's new in the management of acne vulgaris. Cutis. 2019;104(1):48-52. 

2. Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166(6):1691-9.

3. Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. J Drugs Dermatol. 2018;17(3):333-338.

4. Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol. 2014;71(1):70-6.

5. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;(1):CD002086.

6. Jones TM, Ellman H, Devries T. Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. J Drugs Dermatol. 2017;16(10):1022-1028.

7. Raoof J, Hooper D, Moore A, et al. FMX101 4% topical minocycline foam for the treatment of moderate to severe acne vulgaris: efficacy and safety from a phase 3 randomized, double-blind, vehicle-controlled study. Poster presented at: 2018 Fall Clinical Dermatology Conference; October 18-21, 2018; Las Vegas, NV.

8. Gold LS, Del Rosso JQ, Bhatia ND, et al. Efficacy and safety of FMX103 (1.5% minocycline foam) in the treatment of moderate-to-severe papulopustular rosacea: results from two phase 3 randomized, multicenter,
double-blind, vehicle-controlled studies. Poster presented at: 2019 Winter Clinical Dermatology Conference; January 18-23; 2019; Koloa, HI.

9. Smith JA, Narahari S, Hill D, Feldman SR. Tazarotene foam, 0.1%, for the treatment of acne. Expert Opin Drug Saf. 2016;15(1):99-103.

10. Ju Q, Tao T, Hu T, Karadağ AS, Al-khuzaei S, Chen W. Sex hormones and acne. Clin Dermatol. 2017;35(2):130-137.

11. Barros B, Thiboutot D. Hormonal therapies for acne. Clin Dermatol. 2017;35(2):168-172.

12. Hebert A. Clascoterone topical cream, 1%: a novel, topical, local, selective androgen receptor antagonist: results from two phase 3 studies treating children and adult patients with facial acne vulgaris. Presented at: 2019 American Academy of Dermatology Annual Meeting; March 2, 2019; Washington, DC.

13. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014;124(9):3713-24.

14. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87-92.

15. Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod. 2008;71(8):1427-30.

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Melasma and Hyperpigmentation Treatments
  • Treatments for Plaque Psoriasis
  • Derm Pulse
  • Current and Emerging Treatments for Acne
  • Videos Atopic Dermatitis
Treatment of Plaque Psoriasis
The management of Atopic Dermatitis Across the Generations
CME Activities
Advancements in Aesthetics Technology Podcast Series
Discovering the Versatility of the CO2RE Platform to Treat Dermatologic, Aesthetic, and Gynecologic Applications
Derm NP and PA discussion forum

Current Issue

Dermatology Times, December 2019 (Vol. 40, No. 12)
Dec 03, 2019 Vol 40 No 12
Digital Edition
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".